CRESCENT BIOPHARMA, INC. (CBIO) Free cash flow
- Free cash flow · 12 months (USD): Value $-73.62M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -619.52%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-73.62M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-72.68M − $939.00K ≈ $-73.62M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -619.52% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-73.62M ÷ $11.88M × 100 ≈ -619.52% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-72.68M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 6.59× | Operating cash flow / net income. Period ending 2026-06-30. $-72.68M ÷ $-11.03M ≈ 6.59× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -72.68M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 939.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -73.62M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 11.88M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -11.03M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-73.62M | (m) | $-72.68M | $939.00K | (m) | $11.88M | (m) | $-11.03M | (m) | (m) | -619.52% | 6.59× |
| 2026-03-31 | $-70.68M | (m) | $-69.62M | $1.07M | (m) | $11.88M | (m) | $-7.98M | (m) | (m) | -594.83% | 8.72× |
| 2025-12-31 | $-72.45M | (m) | $-71.53M | $919.00K | (m) | $10.84M | (m) | $-153.94M | (m) | (m) | -668.12% | 0.46× |
| 2025-09-30 | $-49.22M | (m) | $-48.50M | $726.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $-39.09M | (m) | $-38.95M | $140.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $-25.70M | (m) | (m) | (m) | (m) | $-29.49M | (m) | (m) | (m) | 0.87× |
| 2024-12-31 | $-31.11M | (m) | $-31.10M | $9.97K | (m) | (m) | (m) | $-37.88M | (m) | (m) | (m) | 0.82× |
| 2024-09-30 | $-35.04M | (m) | $-35.03M | $10.77K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-35.74M | (m) | $-35.72M | $18.64K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-33.83M | (m) | $-33.80M | $26.64K | (m) | (m) | (m) | $-37.28M | (m) | (m) | (m) | 0.91× |
| 2023-12-31 | $-34.90M | (m) | $-34.88M | $21.39K | (m) | (m) | (m) | $-36.90M | (m) | (m) | (m) | 0.95× |
| 2023-09-30 | $-35.20M | (m) | $-35.18M | $20.59K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-35.13M | (m) | $-35.11M | $15.21K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-44.41M | (m) | $-44.37M | $45.87K | (m) | (m) | (m) | $-42.40M | (m) | (m) | (m) | 1.05× |
| 2022-12-31 | $-46.54M | (m) | $-46.46M | $84.19K | (m) | (m) | (m) | $-46.69M | (m) | (m) | (m) | 1.00× |
| 2022-09-30 | $-51.45M | (m) | $-51.36M | $86.64K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-59.78M | (m) | $-59.69M | $88.49K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-57.13M | (m) | $-57.07M | $52.40K | (m) | (m) | (m) | $-63.81M | (m) | (m) | (m) | 0.89× |
| 2021-12-31 | $-57.50M | (m) | $-57.49M | $14.94K | (m) | (m) | (m) | $-63.43M | (m) | (m) | (m) | 0.91× |
| 2021-09-30 | $-54.42M | (m) | $-54.37M | $50.67K | (m) | (m) | (m) | $-61.57M | (m) | (m) | (m) | 0.88× |
| 2021-06-30 | $-48.99M | (m) | $-48.93M | $62.15K | (m) | (m) | (m) | $-57.96M | (m) | (m) | (m) | 0.84× |
| 2021-03-31 | $-49.93M | (m) | $-49.87M | $63.43K | (m) | (m) | (m) | $-57.64M | (m) | (m) | (m) | 0.87× |
| 2020-12-31 | $-39.31M | (m) | $-39.24M | $68.51K | (m) | (m) | (m) | $-51.03M | (m) | (m) | (m) | 0.77× |
| 2020-09-30 | $-42.39M | (m) | $-42.35M | $42.69K | (m) | (m) | (m) | $-50.19M | (m) | (m) | (m) | 0.84× |
| 2020-06-30 | $-44.34M | (m) | $-44.29M | $45.14K | (m) | (m) | (m) | $-49.72M | (m) | (m) | (m) | 0.89× |
| 2020-03-31 | $-41.25M | (m) | $-41.14M | $113.53K | (m) | (m) | (m) | $-51.47M | (m) | (m) | (m) | 0.80× |
| 2019-12-31 | $-52.13M | (m) | $-51.98M | $144.93K | (m) | (m) | (m) | $-57.89M | (m) | (m) | (m) | 0.90× |
| 2019-09-30 | $-49.36M | (m) | $-49.17M | $189.57K | (m) | (m) | (m) | $-57.07M | (m) | (m) | (m) | 0.86× |
| 2019-06-30 | $-46.00M | (m) | $-45.81M | $197.87K | (m) | (m) | (m) | $-55.40M | (m) | (m) | (m) | 0.83× |
| 2019-03-31 | $-47.62M | (m) | $-47.47M | $148.54K | (m) | (m) | (m) | $-50.84M | (m) | (m) | (m) | 0.93× |
| 2018-12-31 | $-43.46M | (m) | $-43.33M | $125.62K | (m) | (m) | (m) | $-48.27M | (m) | (m) | (m) | 0.90× |
| 2018-09-30 | $-41.82M | (m) | $-41.72M | $102.86K | (m) | (m) | (m) | $-43.62M | (m) | (m) | (m) | 0.96× |
| 2018-06-30 | $-37.97M | (m) | $-37.87M | $108.99K | (m) | (m) | (m) | $-40.00M | (m) | (m) | (m) | 0.95× |
| 2018-03-31 | $-31.16M | (m) | $-30.92M | $247.76K | (m) | (m) | (m) | $-36.86M | (m) | (m) | (m) | 0.84× |
| 2017-12-31 | $-30.06M | (m) | $-29.77M | $294.11K | (m) | (m) | (m) | $-33.28M | (m) | (m) | (m) | 0.89× |
| 2017-09-30 | $-28.05M | (m) | $-27.35M | $698.43K | (m) | (m) | (m) | $-32.35M | (m) | (m) | (m) | 0.85× |
| 2017-06-30 | $-29.49M | (m) | $-28.60M | $891.13K | (m) | (m) | (m) | $-32.26M | (m) | (m) | (m) | 0.89× |
| 2017-03-31 | $-30.31M | (m) | $-29.56M | $749.90K | (m) | (m) | (m) | $-32.19M | (m) | (m) | (m) | 0.92× |
| 2016-12-31 | $-30.44M | (m) | $-29.73M | $704.20K | (m) | $18.50K | (m) | $-31.81M | (m) | (m) | -164516.04% | 0.93× |
| 2016-09-30 | $-31.00M | (m) | $-30.73M | $268.86K | (m) | $53.88K | (m) | $-32.36M | (m) | (m) | -57546.15% | 0.95× |
| 2016-06-30 | $-9.80M | (m) | $-9.70M | $101.87K | (m) | (m) | (m) | $-31.68M | (m) | (m) | (m) | 0.31× |
| 2016-03-31 | $-9.05M | (m) | $-8.77M | $283.52K | (m) | (m) | (m) | $-13.22M | (m) | (m) | (m) | 0.66× |
| 2015-12-31 | $-8.51M | (m) | $-8.24M | $268.59K | (m) | $20.07M | (m) | $-12.77M | (m) | (m) | -42.40% | 0.65× |
| 2015-09-30 | $-7.72M | (m) | $-7.44M | $280.23K | (m) | $20.04M | (m) | $-11.28M | (m) | (m) | -38.53% | 0.66× |
| 2015-06-30 | $-26.08M | (m) | $-25.76M | $323.84K | (m) | $20.04M | (m) | $-10.73M | (m) | (m) | -130.17% | 2.40× |
| 2015-03-31 | $-10.60M | (m) | $-10.40M | $201.02K | (m) | $15.03M | (m) | $-13.13M | (m) | (m) | -70.54% | 0.79× |
| 2014-12-31 | $-4.49M | (m) | $-4.28M | $212.60K | (m) | $15.03M | (m) | $-11.12M | (m) | (m) | -29.91% | 0.38× |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-15.62M | (m) | $-15.54M | $82.09K | (m) | $3.99M | (m) | $-10.61M | (m) | (m) | -391.25% | 1.47× |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-10.79M | (m) | $-10.47M | $316.18K | (m) | $15.26M | (m) | $3.66M | (m) | (m) | -70.72% | -2.86× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |